Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. - Wikidata - awgldk - TriplyDB

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

http://www.wikidata.org/entity/Q37214539

about

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes Beta-thalassaemia intermedia: evaluation of endocrine and bone complications.Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.β -thalassemia intermedia in Northern Iraq: a single center experience β-Thalassemia Intermedia: A Bird's-Eye View.Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.Clinical pharmacology of deferasirox.Guidelines for diagnosis and management of Beta-thalassemia intermedia.Management of non-transfusion-dependent thalassemia: a practical guide.Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia.Deferasirox for managing iron overload in people with thalassaemia.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.Revisiting beta thalassemia intermedia: past, present, and future prospects.Morbidities in non-transfusion-dependent thalassemia.Bone quality in beta-thalassemia intermedia: relationships with bone quantity and endocrine and hematologic variables.Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes Serum ferritin level and morbidity risk in transfusion-independent patients with β-thalassemia intermedia: the ORIENT study.Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.Current Standards of Care and Long Term Outcomes for Thalassemia and Sickle Cell Disease.Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation Deferasirox: Over a Decade of Experience in Thalassemia

P2860

Q26771519-380F1502-8CAC-42F3-8C77-08947BB77301 Q33943025-FFE07943-6416-4359-AD0B-DD0D63496128 Q34516223-4E703E78-7812-4558-B47F-8E93CFBE6D70 Q35906193-54C9CE4E-B85B-47B5-83CE-55B3E9DBDEC0 Q37639833-54480971-2242-4873-915E-FDCD11259691 Q37718392-2A17B19C-4BB0-4D0B-801B-D50D909A11EB Q38219588-C7587994-7C23-464D-B31F-49190D2368AD Q38226394-8DD89823-A4BF-4F4D-94AB-9E92AFC5332B Q38253432-51DC7BF2-F937-4982-949A-BE32878381C0 Q38254291-97FFAAD1-4E5C-412D-87A1-5294C7F3D52D Q38423854-18FAD870-3CD6-4E59-AF2C-B9046ABF26DA Q38624033-9EF9F4BF-373A-43F6-A80C-B0822D9025FD Q38650293-F71B0EDA-34E9-40C3-AB39-BA42A9A8699D Q38673817-1950E511-B2A0-410D-B677-069971CABA32 Q38836177-77590991-6852-4436-AA63-54D28A548F5C Q38892046-81D189D7-91D8-4D83-93D6-ED905BF2C78D Q39453693-27591591-ECA7-4E9A-B73E-27121901B9C3 Q42979863-87E52EBF-6251-4BE0-BE65-35AC33F01EBB Q45874313-C9BE3FD2-8A58-49ED-B919-95B3085273BB Q47103242-1F97BDA0-FE1E-4D9F-A8AE-CB80C5574B4F Q47742744-EC9824D8-F7F2-4AE4-81F1-BCA20637A616 Q47771973-00D70B2D-E5A1-4C6C-B442-DB7C56D0B234 Q57515058-CE2080B0-6CE4-47BB-8269-61ACAE090D91 Q58701123-80615605-CA21-4D15-A05D-AE0898F82625

P2860

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study.

http://www.wikidata.org/entity/Q37214539

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Deferasirox effectively reduce ...... sults from the THALASSA study.

@en

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia

@nl

type

label

Deferasirox effectively reduce ...... sults from the THALASSA study.

@en

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia

@nl

prefLabel

Deferasirox effectively reduce ...... sults from the THALASSA study.

@en

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia

@nl

P1433

Q37214539-46D2C8F7-7B9C-4C18-B068-D774E52347DD

P1476

Q37214539-137847E3-68DE-41B4-B1C2-46D06B7F4F2B

P2093

Q37214539-21D866DA-107A-4B9A-B5C0-9B696DFED6D7

Q37214539-22637A5E-7033-4362-9516-A4DA87D0CAD2

Q37214539-319FA1C8-C26E-4324-A94F-E568911C5779

Q37214539-4F6142EA-651E-42DD-9EDE-64E4EA7C6FCF

Q37214539-52104673-B852-470B-9B19-E1AFEFEDE249

Q37214539-611CC2F3-7179-45A6-8EA6-7DBFF0F7B4BE

Q37214539-81D66D38-CB84-4B05-929D-49E51BF34722

Q37214539-87431F8F-3BB6-4342-9CDA-B0EA464E7112

Q37214539-BF242731-E3FF-4C80-A44E-E3767B0A19DF

Q37214539-CF87BDCE-4AB0-40ED-85A4-E0F74C1C06AE

P2860

Q37214539-416339FF-777B-4DB2-AD2C-FA1F4F8BB0DD

Q37214539-6445FDAE-91A2-4A2D-B01A-F3FAF541D262

Q37214539-6AEB4B30-C754-4CCA-B704-6ADDFCBD0A93

Q37214539-8B37EAFE-8348-4857-AFE8-3AD5BBF282FE

Q37214539-9239C2FF-3E9A-404A-84BE-DEA9FF9388F5

Q37214539-97068C81-0447-440C-913D-EFFBA80C7059

Q37214539-DB31DB8A-08AB-4516-8D9C-A817D495C24B

Q37214539-F2BFEA57-AACF-46D8-992E-D43C1AE945F3

Q37214539-F8014B42-D655-4823-9282-48D8BC9DACDE

P304

Q37214539-A90547F5-D563-40B6-B295-D79DF5490C98

P31

Q37214539-C7F15511-0AD1-4311-B007-4C3480FA7E18

P356

Q37214539-CC121891-D377-4A99-A34C-05C3866F5F1E

P433

Q37214539-BFC9ECE5-C688-4949-AC4B-0AEDE9C30D81

P478

Q37214539-BF249FB2-C9F5-442F-8345-9B40493576D6

P50

Q37214539-6DF4EC90-2724-45D1-B510-E050D8B6C565

Q37214539-A9B7B0B1-6FEA-4C55-870F-14F40EE446DC

P577

Q37214539-02069742-4652-4CF1-A750-CD0FD21002DC

P5875

Q37214539-DA39BC94-5DF6-4E4D-B950-FFC8F73CADC6

P698

Q37214539-A11186CF-643B-4394-BD71-53E7146443C4

P932

Q37214539-607E616A-AF0C-457F-A9AF-3D48F3F30396

P356

S00277-013-1808-Z

P1433

Annals of Hematology

P1476

Deferasirox effectively reduce ...... esults from the THALASSA study

@en

P2093

Ali T Taher

http://www.w3.org/2001/XMLSchema#string

Antonis Kattamis

http://www.w3.org/2001/XMLSchema#string

Dany Habr

http://www.w3.org/2001/XMLSchema#string

Jacqueline Ros

http://www.w3.org/2001/XMLSchema#string

Noppadol Siritanaratkul

http://www.w3.org/2001/XMLSchema#string

Pranee Sutcharitchan

http://www.w3.org/2001/XMLSchema#string

Renzo Galanello

http://www.w3.org/2001/XMLSchema#string

Suporn Chuncharunee

http://www.w3.org/2001/XMLSchema#string

Tomasz Lawniczek

http://www.w3.org/2001/XMLSchema#string

Vip Viprakasit

http://www.w3.org/2001/XMLSchema#string

P2860

Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance.

Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia

Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.

Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.

Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study.

Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand.

Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study.

Hepatic iron concentration and total body iron stores in thalassemia major.

Age-related complications in treatment-naïve patients with thalassaemia intermedia

P304

1485-1493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-013-1808-Z

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

Maria Domenica Cappellini

P577

2013-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239734308

http://www.w3.org/2001/XMLSchema#string

P698

23775581

http://www.w3.org/2001/XMLSchema#string

P932

3790249

http://www.w3.org/2001/XMLSchema#string